Search Result

Results for "

obesity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Fat Mass and Obesity-associated Protein (FTO) (15) 11β-HSD (13) 5-HT Receptor (9) Acetyl-CoA Carboxylase (1) Acyltransferase (10) Adenosine Receptor (1) Adrenergic Receptor (13) Akt (3) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (1) AMPK (11) Amylases (3) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (5) AP-1 (1) Apoptosis (23) Aryl Hydrocarbon Receptor (3) ATP Citrate Lyase (3) Autophagy (22) Bacterial (16) Bcl-2 Family (3) Beta-lactamase (1) Biochemical Assay Reagents (3) Bombesin Receptor (1) c-Myc (3) Calcium Channel (5) CaMK (1) Cannabinoid Receptor (17) Carbonic Anhydrase (5) Carboxypeptidase (1) Casein Kinase (5) Caspase (7) CD38 (2) CFTR (4) CGRP Receptor (2) Cholecystokinin Receptor (1) COX (9) CRFR (2) Cytochrome P450 (5) DAGL (3) Dipeptidyl Peptidase (3) Dopamine Receptor (4) Dopamine Transporter (1) Drug Metabolite (1) EGFR (2) ELOVL (1) Endogenous Metabolite (55) Enteropeptidase (2) ERK (4) Estrogen Receptor/ERR (1) FABP (1) Fatty Acid Synthase (FASN) (7) Ferroptosis (6) FOXO (1) Free Fatty Acid Receptor (3) Fungal (1) FXR (3) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (1) Galectin (1) Gap Junction Protein (6) GCGR (22) GHSR (1) GLP Receptor (29) Glucocorticoid Receptor (4) Glucosidase (6) GLUT (3) Glutaminase (1) GnRH Receptor (1) GPR119 (1) GPR139 (1) GSK-3 (1) HCV (2) HDAC (1) HIF/HIF Prolyl-Hydroxylase (4) Histamine Receptor (1) Histone Demethylase (1) HIV (1) HIV Integrase (1) HSP (3) IKK (2) Influenza Virus (6) Insulin Receptor (7) Interleukin Related (5) Isotope-Labeled Compounds (15) JNK (2) Keap1-Nrf2 (2) Ketohexokinase (2) LDLR (1) Liposome (1) MAGL (2) MCHR1 (GPR24) (6) MEK (1) Melanocortin Receptor (9) Melatonin Receptor (1) MetAP (3) Microsomal Triglyceride Transfer Protein (MTP) (1) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (7) Mixed Lineage Kinase (1) MMP (3) Monoamine Oxidase (5) Neuropeptide FF Receptor (2) Neuropeptide Y Receptor (8) NF-κB (7) NO Synthase (3) NOD-like Receptor (NLR) (3) Nuclear Hormone Receptor 4A/NR4A (2) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) Organoid (1) P-glycoprotein (5) Parasite (3) PARP (2) PCSK9 (2) PD-1/PD-L1 (1) PDHK (2) PGE synthase (1) Phosphatase (7) Phospholipase (2) PI3K (7) PKA (1) Potassium Channel (7) PPAR (35) Pyruvate Kinase (2) Ras (1) Reactive Oxygen Species (7) Ribosomal S6 Kinase (RSK) (1) SARS-CoV (5) Ser/Thr Protease (2) Serotonin Transporter (1) SGLT (1) Sirtuin (10) SOD (2) STAT (2) Stearoyl-CoA Desaturase (SCD) (3) Succinate Receptor 1 (1) TGF-β Receptor (2) Thyroid Hormone Receptor (3) TNF Receptor (1) Toll-like Receptor (TLR) (3) TRP Channel (8) Tryptophan Hydroxylase (1) Tyrosinase (2) VEGFR (1) Wnt (1) Xanthine Oxidase (2) α-synuclein (1) β-catenin (1)
By Research Areas:	Cancer (110) Cardiovascular Disease (34) Endocrinology (24) Infection (30) Inflammation/Immunology (99) Metabolic Disease (374) Neurological Disease (67)
Oligonucleotides:	Fillers (1) Phospholipids (1) Antisense Oligonucleotides (2) Cholesterol (1)

478

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

116

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

N6,2′-O-Dimethyladenosine	Fat Mass and Obesity-associated Protein (FTO)	Metabolic Disease
N6,2′-O-Dimethyladenosine, a substrate of fat mass and obesity-associated gene (FTO), is a reversible modification widely occurred on varied RNA molecules. N6,2′-O-Dimethyladenosine can regulate obesity .

(S)-Bexicaserin	5-HT Receptor	Neurological Disease
(S)-Bexcaserin (compound 2) is a 5-HT_2C receptor agonist with potential for studying obesity and psychiatric-related diseases .

GW-803430 GW-3430	MCHR1 (GPR24)	Metabolic Disease
GW-803430 (GW-3430) is a potent and selective melanin-concentrating hormone receptor 1 (MCH R1) antagonist with a pIC₅₀ of 9.3. GW-803430 is orally active in an animal model of obesity .

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

PSB-CB5	Others	Metabolic Disease
PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity .

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .

XN methyl pyrazole XP	Others	Metabolic Disease Cancer
XN methyl pyrazole improves diet-induced obesity and induces energy expenditure in high-fat diet-fed mice .

Cevoglitazar LBM-642	PPAR	Metabolic Disease
Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .

L-796568	Adrenergic Receptor	Metabolic Disease
L-796568 is a β(3)-adrenergic receptor agonist. L-796568 can be used for the research of obesity .

12-OAHSA	Endogenous Metabolite	Metabolic Disease
12-OAHSA is a component of olive oil. 12-OAHSA has oral activity, and improves glucose homeostasis in insulin resistant obese mice .

BMS-194449	Adrenergic Receptor	Metabolic Disease
BMS-194449 is a beta 3 receptor agonist with the K_i value of 160 nM. BMS-194449 can be used for study of obesity and non-insulin dependent diabetes .

GPR61 Inverse agonist 1	Others	Metabolic Disease
GPR61 Inverse agonist 1 (Compound 1) is a GPR61 inverse agonist (IC₅₀: 11 nM). GPR61 Inverse agonist 1 can be used for research of disorders of metabolism and body weight, such as obesity and cachexia .

GPAT-IN-1	Others	Metabolic Disease
GPAT-IN-1 is a glycerol-3-phosphate acyltransferase (GPAT) inhibitor with an IC₅₀ value of 8.9 μM. GPAT-IN-1 can be used for the research of obesity .

N-Lactoyl-Phenylalanine Lac-Phe	Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

Hippuryl-L-phenylalanine	Carboxypeptidase	Cancer
Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity .

20-HETE inhibitor-2	Others	Metabolic Disease
GPR75 antagonist-2 is an antagonist of GPR75. GPR75 antagonist-2 can used in study obesity and insulin resistance .

SH-BC-893	Mitochondrial Metabolism	Metabolic Disease Cancer
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity .

DGAT-1 inhibitor 3	Acyltransferase	Metabolic Disease
DGAT-1 inhibitor 3 (compound 10) is a potent DGAT-1 inhibitor with an IC₅₀ value of 0.038 µM. DGAT-1 inhibitor 3 has the potential for the research of obesity and diabetes .

Turanose	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research .

Bexicaserin	Others	Others
Bexicaserin (Compound 3) is a 5-HT2C receptor agonist with potential for studying obesity and psychiatric-related diseases .

Tri-Salicylic acid	Others	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Tri-Salicylic acid is the compound with similar properties of salicylic acid. Tri-Salicylic acid has the potential for the research of inflammation, obesity and cardiovascular diseases (extracted from patent US20170368079A1, compound III) .

NCRW0005-F05	GPR139	Neurological Disease Metabolic Disease
NCRW0005-F05 is a potent GPR139 antagonist with an IC₅₀ value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's disease .

JTP-103237	Acyltransferase	Metabolic Disease
JTP-103237 is a MGAT2 inhibitor (IC₅₀: 0.019 μM and 6.423 μM for hMGAT2 and hMGAT3 respectively). JTP-103237 modulates fat absorption, decreases plasma glucose levels and prevents diet-induced obesity .

Glucocorticoids receptor agonist 3	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
Glucocorticoids receptor agonist 3 is a potent agonist of glucocorticoids receptor. Glucocorticoids receptor agonist 3 is useful to research diseases, such as obesity, diabetes, and inflammation (extracted from patent WO2000066522A1, compound 345) .

4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside	Endogenous Metabolite	Metabolic Disease
4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside is a pancreatic lipase inhibitor, with an IC₅₀ value of 2.91 μM. 4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside can effectively reduce lipid absorption and regulate obesity-related metabolic disorders, making it useful for research on obesity .

M77976 1 Publications Verification	PDHK	Metabolic Disease
M77976 is a specific ATP-competitive inhibitor of PDK4 (pyruvate dehydrogenase kinase isoforms 4), with an IC₅₀ of 648 μM. M77976 is potential for the research of obesity and diabetes .

3,4,5-Trihydroxycinnamic acid decyl ester	Others	Metabolic Disease
3,4,5-Trihydroxycinnamic acid decyl ester is an excellent inhibitor of lipid absorption and accumulation, with anti-obesity properties. 3,4,5-Trihydroxycinnamic acid decyl ester is a pancreatic lipase inhibitor, with an EC₅₀ of approximately 0.9 μM .

Bivamelagon MC-4R Agonist 2	Melanocortin Receptor	Inflammation/Immunology
MC-4R Agonist 2 (Example 1) is a MC4R agonist. MC-4R Agonist 2 can be used in the study of obesity, diabetes, inflammation, and erectile dysfunction .

Bivamelagon hydrochloride MC-4R Agonist 2 hydrochloride	Melanocortin Receptor	Inflammation/Immunology
MC-4R Agonist 2 hydrochloride (Example 1) is a MC4R agonist. MC-4R Agonist 2 hydrochloride can be used in the study of obesity, diabetes, inflammation, and erectile dysfunction .

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

XEN103	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
XEN103 is a SCD1 inhibitor, with IC₅₀s of 14 nM and 12 nM for mSCD1 and SCD1 in HepG2 cell. XEN103 can be used for research of obesity and type 2 diabetes. XEN103 also induces sebaceous gland atrophy in mice .

Uvagrandol	Glucosidase	Metabolic Disease
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC₅₀: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity .

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

Phosphatidylcholine transfer protein inhibitor-1	Others	Metabolic Disease
Phosphatidylcholine transfer protein inhibitor-1 (Answer 37 in Patent) is a phosphatidylcholine transfer protein (PC-TP) inhibitor. Phosphatidylcholine transfer protein inhibitor-1 can be used for research of PC-TP related disease such as obesity .

GLP-1 receptor agonist 8	GCGR	Metabolic Disease
GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) .

Maridebart cafraglutide AMG 133	GLP Receptor	Metabolic Disease
Maridebart cafraglutide is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity .

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .

HMR1426	Others	Metabolic Disease
HMR1426 is an orally active, potent gastric emptying inhibitor. HMR1426 reduces food intake and the rate of gastric emptying, decreases body weight and fat mass and shows an anorectic potential in rats. HMR1426 has the potential for obesity research .

Ibipinabant SLV319; BMS-646256	Cannabinoid Receptor	Metabolic Disease
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a K_i of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic .

UNC7467	Others	Others
UNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research .

Rafabegron AJ‐9677	Adrenergic Receptor	Metabolic Disease
Rafabegron (AJ-9677) is a specific beta3-adrenoceptor agonist. Rafabegron can reduce blood glucose, insulin, FFA, and triglyceride levels in diabetic and obese mouse models .

SE-7552	HDAC	Metabolic Disease Cancer
SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC₅₀ of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice .

PTP1B-IN-15	Phosphatase	Endocrinology
PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity .

GLP-1 receptor agonist 10	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity .

SUCNR1-IN-1	Succinate Receptor 1	Inflammation/Immunology
SUCNR1-IN-1 (Compound 20) is a SUCNR1 inhibitor (IC₅₀: 88 nM for hSUCNR1). SUCNR1-IN-1 can be used for research of rheumatoid arthritis, liver fibrosis, or obesity .

MCHR1 antagonist 4	MCHR1 (GPR24)	Others
MCHR1 antagonist 4 (Compound 2m) is a blood-brain barrier permeable MCHR1 antagonist with K_i values of 0.74 nM and 0.76 nM for hMCHR1 and rMCHR1, respectively. MCHR1 antagonist 4 is also an effective anti-obesity agent .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library

2,506 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,506 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,176 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,176 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

HY-L091

Lipid Metabolism Compound Library

678 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 678 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

HY-L146

Metabolic Enzyme Compound Library

3,038 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms that maintain cell homeostasis. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of molecules including glucose metabolism, lipid metabolism and amino acid or protein metabolism within a cell or tissue. As catalysts, enzymes are crucial to metabolism as they allow a reaction to proceed more rapidly and tregulate the rate of a metabolic reaction. Due to the importance of metabolic balance in the organism, the abnormal function of metabolic enzymes often leads to the occurrence of a variety of metabolic diseases, such as diabetes, obesity, cardiovascular disease, etc.

MCE designs a unique collection of 3,038 metabolic enzymes related small molecules, which is an important tool for studying the metabolic activities of organisms and developing drugs for metabolic diseases.

HY-L078

Gut Microbial Metabolite Library

500 compounds

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 500 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

HY-L123

Human Metabolite Library

6,157 compounds

Human metabolism is an integral part of cellular function that reflects individual differences in health, disease, diet, and lifestyle. Many health conditions such as obesity, diabetes, hypertension, heart disease, and cancer are associated with abnormal metabolic states. In the pathological state of the human body, metabolic pathways are significantly altered, resulting in aberrant levels of intermediates or end-products that can be viewed as potential diagnostic biomarkers or even therapeutic targets. Therefore, detection, identification and quantification of human metabolites are very important for drug metabolism research in drug development.

MCE offers a unique collection of 6,157 human metabolites, including endogenous metabolites and exogenous metabolites, covering multiple structure types, such as lipids, amino acids, nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins,. MCE Human Metabolites Library is a helpful tool for studying the relationship between diseases and metabolism.

HY-L103

Anti-Colorectal Cancer Compound Library

1,718 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,718 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-13012G

RepSox (GMP) E-616452 (GMP); SJN 2511 (GMP)	Fluorescent Dye
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

Cat. No.	Product Name	Type

HY-137840

Hippuryl-L-phenylalanine	Enzyme Substrates
Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity .

HY-124187

Pinolenic acid ethyl ester

Ethyl pinolenate

Drug Delivery

Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

HY-13012G

RepSox (GMP) E-616452 (GMP); SJN 2511 (GMP)	Biochemical Assay Reagents
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

HY-W013063

1,2-Dilinoleoyl-sn-glycero-3-phosphocholine	Drug Delivery
1,2-Dilinoleoyl-sn-glycero-3-phosphocholine is a phospholipid. 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine can be used for obesity research .

Cat. No.	Product Name	Target	Research Area

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P3462

Cagrilintide	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P2378

Neuromedin U-25 (human)	Peptides	Cardiovascular Disease
Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .

HY-P3134

CPN-267	Peptides	Metabolic Disease
CPN-267 (compound 7b) is a selective neuromedin U receptor 1 (NMUR1) agonist with the EC₅₀ of 0.25 nM. CPN-267 suppresses body weight gain in mice and can be used for study of obesity .

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-P10378

GPR10 agonist 1	GnRH Receptor	Metabolic Disease
GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC₅₀ values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity .

HY-P3848

Tyr0-Neurokinin A	Peptides	Neurological Disease Metabolic Disease
Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes .

HY-P1432

K-(D-1-Nal)-FwLL-NH2	GHSR	Metabolic Disease
K-(D-1-Nal)-FwLL-NH2 is a high affinity, potent and inverse ghrelin receptor agonist (EC₅₀=3.4 nM, K_i=4.9 nM). K-(D-1-Nal)-FwLL-NH2 can be used for the research of obesity .

HY-P3677

Neuropeptide Y (2-36) (porcine)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y (2-36) (porcine) is a porcine-derived neuropeptide with 97.14% homology to rat/human origin. Neuropeptide Y (2-36) (porcine) is also a rat neuropeptide receptor agonist, with EC₅₀ values of 1.2, 1.6 and 3.4 nM for receptor of Y5, Y2 and Y1 respectively. Neuropeptide Y (2-36) (porcine) can be used in studies related to obesity and eating disorders .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors. SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P1230

HAEGT	Dipeptidyl Peptidase GLP Receptor	Metabolic Disease
HAEGT is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity .

HY-P1624

Teduglutide 1 Publications Verification ALX-0600	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P1624A

Teduglutide TFA ALX-0600 TFA	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2048A

MOTS-c(human) acetate	AMPK GLUT	Metabolic Disease
MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity .

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .

HY-P3580A

Acetyl Gastric Inhibitory Peptide (human) (TFA) Human N-acetyl GIP TFA	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P3506

Retatrutide LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P3506A

Retatrutide TFA LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P3866

[Asu1,6]-Oxytocin	Peptides	Metabolic Disease
[Asu1,6]-Oxytocin is an analog of oxytocin. [Asu1,6]-Oxytocin reverses insulin resistance and glucose intolerance prior to reduction of obesity. [Asu1,6]-Oxytocin has the potential for the research of obesity and diabetes .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P10026

Nisotirostide LY-3457263	Peptides	Metabolic Disease
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P1910

BDC2.5 mimotope 1040-51	Peptides	Metabolic Disease
BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice .

HY-P3341

OB3	Peptides	Metabolic Disease Inflammation/Immunology Cancer
OB3, a derivative of Leptin, show more effective than leptin in reducing obesity and diabetes in mouse models. OB3 can reduce Leptin-related inflammation and proliferation in hepatocellular carcinoma cells .

HY-138119A

γ-Glutamylserine TFA γ-Glu-Ser TFA	Calcium Channel	Metabolic Disease
γ-Glutamylserine TFA (γ-Glu-Ser TFA) is a calcium receptor activator. γ-Glutamylserine TFA can be used for Parkinson's disease research, as well as diabetes or obesity study .

HY-P3586

HKPao Hunter-killer peptide ao; Prohibitin-targeting peptide 1; prohibitin-TP01; Adipotide	Apoptosis	Cancer
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles .

HY-P4860

Adropin (34-76) (human, mouse, rat)	Akt	Metabolic Disease
Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle. Adropin increases insulin-induced Akt phosphorylation and cell-surface expression of GLUT4, in diet-induced obesity (DIO) mouse.

HY-P10397

YHIEPV rALP-2, Rubisco anxiolytic-like peptide 2	Peptides	Neurological Disease Metabolic Disease
YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects .

HY-P4815

Prokineticin 2 Isoform 2 (human)	Endogenous Metabolite	Neurological Disease Metabolic Disease
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .

HY-P10377

GUB03385	Neuropeptide FF Receptor	Metabolic Disease
GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC₅₀: 0.4 nM) and NPFF2R (partial agonist, EC₅₀: 20 nM). GUB03385 has anti-obesity effect .

HY-P4657

Human Growth Hormone (1-43)	Peptides	Endocrinology
Human Growth Hormone (1-43) is an N-terminal fragment of human growth hormone with specific and pronounced insulin-like activity. Human Growth Hormone (1-43) can be used to study the function and metabolic pathways of growth hormone, a potential obesity-related factor .

HY-P5489

IGRP(206-214)	Peptides	Others
IGRP(206-214) is a biological active peptide. (This peptide corresponds to residues 206–214 of murine islet-specific glucose-6-phosphatase catalytic subunit–related protein (IGRP). This peptide is T cells specific for proinsulin and IGRP induces diabetes in non-obese diabetic (NOD) mice.)

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect .

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect .

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-P3584A

(Pro3) GIP, human TFA (Pro3) Gastric Inhibitory Peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

HY-P3584

(Pro3) GIP, human (Pro3) Gastric Inhibitory Peptide, human	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with K_i/ K_d values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10312

SPN009	GLP Receptor	Metabolic Disease
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC₅₀ of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .

HY-P1238

Neuromedin U, rat Neuromedin U (rat); Rat neuromedin U-23	Peptides	Neurological Disease
Neuromedin U, rat is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.

Species:	Human (6) Rat (2) Mouse (2)
Tag:	His (6) Tag Free (4) Fc (2) Flag (1)
Source:	HEK293 (2) P. pastoris (1) E. coli (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P7232

	Leptin Protein, Human 1 Publications Verification rHuLeptin; obesity protein; OB	Human	E. coli
	Leptin Protein, Human is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P7233

	Leptin Protein, Rat 1 Publications Verification rRtLeptin; obesity protein (OB)	Rat	E. coli
	Leptin Protein, Rat is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P7232A

	Leptin Protein, Human (His) rHuLeptin; obesity protein; OB	Human	E. coli
	Leptin is an important energy regulator that regulates appetite, metabolism, and immune responses through its central receptor LEPR. In the hypothalamus, it reduces food intake, affects neuropeptides, and affects bone mass and reproductive function. Leptin Protein, Human (His) is the recombinant human-derived Leptin protein, expressed by E. coli , with N-6*His labeled tag. The total length of Leptin Protein, Human (His) is 146 a.a., with molecular weight of ~17 kDa.

HY-P7233A

	Leptin Protein, Rat (His) rRtLeptin; obesity protein (OB)	Rat	E. coli
	Leptin Protein, Rat is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P70704

	Leptin Protein, Mouse 1 Publications Verification Leptin; Obese Protein; obesity Factor; LEP; OB; OBS	Mouse	E. coli
	Leptin Protein, Mouse is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P70704A

	Leptin Protein, Mouse (His) Leptin; Obese Protein; obesity Factor; LEP; OB; OBS	Mouse	E. coli
	Leptin is a key regulator of energy balance and body weight and binds to LEPR receptors in multiple tissues.It controls appetite in the hypothalamus and affects bone mass, hormone regulation, and reproductive function.Leptin Protein, Mouse (His) is the recombinant mouse-derived Leptin protein, expressed by E.coli , with N-6*His labeled tag.

HY-P70181

	Leptin Protein, Carassius auratus (P.pastoris, His) rCaLeptin, His; Leptin; Obese Protein; obesity Factor; LEP; OB; OBS	Others	P. pastoris
	Leptin protein plays a pivotal role in regulating energy balance and body weight. It binds to its receptor, LEPR, in various tissues, activating signaling pathways that regulate energy homeostasis. Leptin Protein, Carassius auratus (P.pastoris, His) is the recombinant Leptin protein, expressed by P. pastoris , with N-8*His labeled tag. The total length of Leptin Protein, Carassius auratus (P.pastoris, His) is 150 a.a., with molecular weight of ~17.0 kDa.

HY-P71023

	Siglec-5 Protein, Human (HEK293, His-Flag-Fc) Sialic acid-binding Ig-like lectin 5; Siglec-5; CD33 antigen-like 2; obesity-binding protein 2; OB-BP2; CD170	Human	HEK293
	Siglec-5 Protein, a putative adhesion molecule, participates in sialic-acid dependent cellular binding, showing equal affinity for alpha-2,3-linked and alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked through cis interactions with sialic acids on the same cell surface. Siglec-5 Protein, Human (HEK293, His-Flag-Fc) is the recombinant human-derived Siglec-5 protein, expressed by HEK293 , with C-hFc, C-Flag, C-6*His labeled tag. The total length of Siglec-5 Protein, Human (HEK293, His-Flag-Fc) is 418 a.a., with molecular weight of 90-110 kDa.

HY-P701887

	FTO Protein, Human FTO; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein; U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO; mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; m6A(m)-demethylase FTO; mRNA N(6)-methyladenosine demethylase FTO; tRNA N1-methyl adenine demethylase FTO	Human	E. coli
	FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human is the recombinant human-derived FTO protein, expressed by E. coli , with tag free. The total length of FTO Protein, Human is 474 a.a., .

HY-P72471

	Siglec-5 Protein, Human (HEK293, Fc) Sialic acid-binding Ig-like lectin 5; Siglec-5; CD33 antigen-like 2; obesity-binding protein 2; OB-BP2; CD170	Human	HEK293
	Siglec-5 Protein, a putative adhesion molecule, participates in sialic-acid dependent cellular binding, showing equal affinity for alpha-2,3-linked and alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked through cis interactions with sialic acids on the same cell surface. Siglec-5 Protein, Human (HEK293, Fc) is the recombinant human-derived Siglec-5 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-5 Protein, Human (HEK293, Fc) is 418 a.a., with molecular weight of 90-110 kDa.

HY-P701888

	FTO Protein, Human (His) FTO; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein; U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO; mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; m6A(m)-demethylase FTO; mRNA N(6)-methyladenosine demethylase FTO; tRNA N1-methyl adenine demethylase FTO	Human	E. coli
	FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human (His) is the recombinant human-derived FTO protein, expressed by E. coli , with N-6*His labeled tag. The total length of FTO Protein, Human (His) is 474 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-F0004S

β-Nicotinamide mononucleotide-d4

β-Nicotinamide mononucleotide-d₄ is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

HY-W015464S

N-Isovalerylglycine-d9
N-Isovalerylglycine-d₉ is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-107542S

Oleoylethanolamide-d4
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-15206S1

Glyburide-d3

Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-B1779S3

Sucrose-d14
Sucrose-d₁₄ is the deuterium labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preferen

HY-W768338

Sucrose-13C
Sucrose- ¹³C is ¹³C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .

HY-W768340

Sucrose-13C6-1
Sucrose- ¹³C₆-1 is ¹³C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .

HY-W015464S1

N-Isovaleroylglycine-d2
N-Isovaleroylglycine-d₂ is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-107542S2

Oleoylethanolamide-d2
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-15206S

Glyburide-d11

Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-W017212S

Methyl cinnamate-d7
Methyl cinnamate-d₇ is deuterated labeled Cinnamyl Alcohol (HY-Y0078). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, with anti-obesity activity .

HY-W020183S

γ-Terpinene-d3
γ-Terpinene-d₃ is deuterated labeled Cinnamyl Alcohol (HY-Y0078). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, with anti-obesity activity .

HY-B0218S

Orlistat-d3
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .

HY-117275S1

Meclofenamic acid-13C6
Meclofenamic acid- ¹³C₆ is the ¹³C₆ labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.

HY-B1779S5

Sucrose-13C6
Sucrose-13C6 is the 13C labeled Sucrose[1]. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al[2].

HY-117275S

Meclofenamic acid-d4
Meclofenamic acid-d₄ is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker[1][2][3].

HY-17386S1

Rosiglitazone-d4
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-18260S1

Bisphenol A-d6

Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].

HY-18260S

Bisphenol A-d16

Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S4

Bisphenol A-d4

Bisphenol A-d₄ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S6

Bisphenol A-d14

Bisphenol A-d₁₄ is a deuterium labeled Bisphenol A (HY-18260). Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-18260S3

Bisphenol A-d8

Bisphenol A-d₈ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].

HY-18260S5

Bisphenol A-d4-1

Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-N0055S

Chlorogenic acid-13C3

Chlorogenic acid- ¹³C₃ (Heriguard- ¹³C₃; NSC-407296- ¹³C₃) is ¹³C- and ¹⁵N-labeled Chlorogenic acid (HY-N0055). Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb.. It plays several important and therapeutic roles such as antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension .

HY-104026BS

L-Kynurenine-13C10 sulfate
L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-104026CS

L-Kynurenine-13C10 sulfate hemihydrate
L-Kynurenine- ¹³C10 (sulfate hemihydrate) is the ¹³C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81241

	Leptin Antibody LEP; Leptin Murine obesity Homolog; Leptin Precursor obesity Factor; OB; Obese Protein; obesity; obesity factor; obesity homolog mouse; obesity Murine Homolog Leptin; OBS; LEP_HUMAN.	IHC-P, IHC-F, ICC/IF, ELISA	Human, Mouse, Rat, Pig, Sheep
	Leptin Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Leptin, with a predicted molecular weight of 16 kDa . Leptin Antibody can be used for IHC-P, IHC-F, ICC/IF, ELISA experiments in human, mouse, rat, pig, sheep backgrounds.

HY-P80680

	FTO Antibody FTO; KIAA1752; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein	WB, IHC-P	Human
	FTO Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 58 kDa, targeting to FTO. It can be used for WB,IHC-P assays with tag free, in the background of Human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-B1779

Sucrose 5 Publications Verification D-(+)-Saccharose		Fillers
Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al .

HY-N4103

Fucosterol		Cholesterol
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .